Olivier L. Chinot
Marseille neuro-oncologist who was lead author of AVAglio, the trial that showed adding bevacizumab to standard glioblastoma treatment delays progression but does not lengthen life.
Overview
Olivier Chinot leads neuro-oncology at Hôpital de la Timone in Marseille. He was first author of the 2014 New England Journal of Medicine report of AVAglio, the phase 3 trial in which bevacizumab added to radiotherapy and temozolomide improved progression-free survival but not overall survival in newly diagnosed glioblastoma, a result echoed by the parallel RTOG 0825 trial and which limited the drug's role in the disease.
Similar pages
not linked directly; found by shared links- PersonAndrew B. Lassman
Shares Brain and spinal cord tumours (all types), Glioma & glioblastoma and the tags brain, trialist.
- PersonJan C. Buckner
Shares Brain and spinal cord tumours (all types) and the tags brain, trialist.
- PersonScott R. Plotkin
Shares Brain and spinal cord tumours (all types) and the tags brain, trialist.
- PersonJacques Grill
Shares Glioma & glioblastoma and the tags brain, trialist.
- PersonPaul D. Brown
Shares Brain and spinal cord tumours (all types) and the tags brain, trialist.
- PersonSarah E. S. Leary
Shares the tags brain, trialist.
- PersonFlorence Duffaud
Shares Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille and the tag trialist.
- PersonJean-Jacques Grob
Shares Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille and the tag trialist.